UCB (EBR:UCB) UCB Media Room: Praxis Precision Medicines Epilepsy Research Collaboration

Directive transparence : information réglementée

13/12/2022 22:05
https://mb.cision.com/Public/18595/3684074/bc2520ed98a73851_800x800ar.png ** UCB and Praxis Precision Medicines Announce Epilepsy Research Collaborat= ion ------------------------------------------------------------ BRUSSELS (Belgium) and BOSTON, Massachusetts (USA), December 13th, 2022 (22= :01 CET) =E2=80=94 UCB, a global biopharmaceutical company (EURONEXT BRUSSE= LS: UCB), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-s= tage biopharmaceutical company, today announced a strategic collaboration, = based upon Praxis=E2=80=99 PRAX-020 program, for the discovery of small mol= ecule therapeutics as potential treatments of KCNT1 related epilepsies. =E2=80=9CWe are excited to partner with UCB, a global leader in epilepsy dr= ug development, as we work together toward a novel approach for the treatme= nt of KCNT1 related epilepsy, which has no approved therapies currently,=E2= =80=9D said Marcio Souza, president and chief executive officer of Praxis. = =E2=80=9COur internal research efforts give us confidence that small molecu= les can selectively inhibit the KCNT1 channel, and potentially could be an = effective treatment for individuals suffering from KCNT1 related epilepsy. = The collaboration with UCB validates this approach and will allow us to acc= elerate efforts toward a potential treatment for KCNT1 patients.=E2=80=9D Under the terms of the collaboration, UCB retains an exclusive option to in= -license global development and commercialization rights to any resulting K= CNT1 small molecule development candidate. Praxis will receive an upfront p= ayment from UCB, and if the option is exercised by UCB, would be eligible t= o receive an option fee and future success-based development and commercial= ization milestone payments, for a total of up to approximately $100 million= , in addition to tiered royalties on net sales of any resulting products fr= om the collaboration. Further financial details of the agreement were not d= isclosed. =E2=80=9CUCB is dedicated to the discovery and development of treatments fo= r epilepsy, including rare and genetic epilepsies, with an ambition to deve= lop solutions that move from symptomatic relief to those that could address= the root causes of disease,=E2=80=9D said Dhaval Patel, chief scientific o= fficer of UCB. =E2=80=9CPraxis=E2=80=99 genetics-driven approach has led to= compelling preclinical proof of concept, and we look forward to progressin= g this novel research program together for the benefit of individuals and f= amilies affected by this devastating form of epilepsy.=E2=80=9D About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 8,600 people in= approximately 40 countries, UCB generated revenue of =E2=82=AC5.8 billion = in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twi= tter: @UCB_news Forward looking statements - UCB This press release may contain forward-looking statements including, withou= t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, = =E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends= =E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim= ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont= inue=E2=80=9D and similar expressions. These forward-looking statements are= based on current plans, estimates and beliefs of management. All statement= s, other than statements of historical facts, are statements that could be = deemed forward-looking statements, including estimates of revenues, operati= ng margins, capital expenditures, cash, other financial information, expect= ed legal, arbitration, political, regulatory or clinical results or practic= es and other such estimates and results. By their nature, such forward-look= ing statements are not guarantees of future performance and are subject to = known and unknown risks, uncertainties and assumptions which might cause th= e actual results, financial condition, performance or achievements of UCB, = or industry results, to differ materially from those that may be expressed = or implied by such forward-looking statements contained in this press relea= se. Important factors that could result in such differences include: the gl= obal spread and impact of COVID-19, changes in general economic, business a= nd competitive conditions, the inability to obtain necessary regulatory app= rovals or to obtain them on acceptable terms or within expected timing, cos= ts associated with research and development, changes in the prospects for p= roducts in the pipeline or under development by UCB, effects of future judi= cial decisions or governmental investigations, safety, quality, data integr= ity or manufacturing issues; potential or actual data security and data pri= vacy breaches, or disruptions of our information technology systems, produc= t liability claims, challenges to patent protection for products or product= candidates, competition from other products including biosimilars, changes= in laws or regulations, exchange rate fluctuations, changes or uncertainti= es in tax laws or the administration of such laws, and hiring and retention= of its employees. There is no guarantee that new product candidates will b= e discovered or identified in the pipeline, will progress to product approv= al or that new indications for existing products will be developed and appr= oved. Movement from concept to commercial product is uncertain; preclinical= results do not guarantee safety and efficacy of product candidates in huma= ns. So far, the complexity of the human body cannot be reproduced in comput= er models, cell culture systems or animal models. The length of the timing = to complete clinical trials and to get regulatory approval for product mark= eting has varied in the past and UCB expects similar unpredictability going= forward. Products or potential products, which are the subject of partners= hips, joint ventures or licensing collaborations may be subject to differen= ces disputes between the partners or may prove to be not as safe, effective= or commercially successful as UCB may have believed at the start of such p= artnership. UCB=E2=80=99s efforts to acquire other products or companies an= d to integrate the operations of such acquired companies may not be as succ= essful as UCB may have believed at the moment of acquisition. Also, UCB or = others could discover safety, side effects or manufacturing problems with i= ts products and/or devices after they are marketed. The discovery of signif= icant problems with a product similar to one of UCB=E2=80=99s products that= implicate an entire class of products may have a material adverse effect o= n sales of the entire class of affected products. Moreover, sales may be im= pacted by international and domestic trends toward managed care and health = care cost containment, including pricing pressure, political and public scr= utiny, customer and prescriber patterns or practices, and the reimbursement= policies imposed by third-party payers as well as legislation affecting bi= opharmaceutical pricing and reimbursement activities and outcomes. Finally,= a breakdown, cyberattack or information security breach could compromise t= he confidentiality, integrity and availability of UCB=E2=80=99s data and sy= stems.=C2=A0 Given these uncertainties, you should not place undue reliance on any of su= ch forward-looking statements. There can be no guarantee that the investiga= tional or approved products described in this press release will be submitt= ed or approved for sale or for any additional indications or labelling in a= ny market, or at any particular time, nor can there be any guarantee that s= uch products will be or will continue to be commercially successful in the = future. UCB is providing this information, including forward-looking statements, on= ly as of the date of this press release and it does not reflect any potenti= al impact from the evolving COVID-19 pandemic, unless indicated otherwise. = UCB is following the worldwide developments diligently to assess the financ= ial significance of this pandemic to UCB. UCB expressly disclaims any duty = to update any information contained in this press release, either to confir= m the actual results or to report or reflect any change in its forward-look= ing statements with regard thereto or any change in events, conditions or c= ircumstances on which any such statement is based, unless such statement is= required pursuant to applicable laws and regulations.=C2=A0 Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. For further information R&D Communications - UCB Scott Fleming Scott.fleming@ucb.com / +44 7702777378 Investor Relations - UCB Antje Witte antje.witte@ucb.com / +32.2.559.94.14 Investor Contact - Praxis Alex Kane=C2=A0 Praxis Precision Medicines investors@praxismedicines.com / 617-300-8481 Media Contact - Praxis Ian Stone Canale Communications Ian.stone@canalecomm.com / 619-849-5388 =C2=A0 GenericFile FINAL UCB PRAXIS Release (https://mb.cision.com/Public/18595/3684074/bfaa80= f8f4358fd4.pdf) ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x124336x1x6868579x2400= 0x6&Email=3Dregnews%40symexglobal.com. UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium